Valuation: Mendus AB

Market Cap 414M 42.69M 37.5M 34.87M 32M 60.13M 4.11B 61.05M 162M 2.02B 160M 157M 6.99B P/E 2026 *
-4.42x
P/E 2027 * -7.51x
Enterprise Value 92.8M 9.57M 8.4M 7.82M 7.17M 13.47M 921M 13.68M 36.26M 453M 35.92M 35.14M 1.57B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 0.97x
Free-Float
34.33%
Yield 2026 *
-
Yield 2027 * -
1 day-0.96%
1 week+8.50%
Current month+12.44%
1 month-1.51%
3 months+32.86%
6 months+16.25%
Current year+16.25%
1 week 6
Extreme 6
6.95
1 month 5.55
Extreme 5.55
7.24
Current year 3.86
Extreme 3.86
7.49
1 year 3.86
Extreme 3.86
10.86
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 16/03/2021
Chief Executive Officer 76 13/12/2019
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
28/2/22 Buy

Chief Technology Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
-3.56%+8.50%-34.90%-30.08% 42.38M
+1.07%-3.49%-3.25%+12.87% 46.35B
+0.26%+1.84%+409.38%+630.88% 40.13B
-0.18%+4.37%+9.84%+66.79% 36.33B
+0.98%+1.47%+4.22%-8.27% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+1.21%-1.39% - - 16.66B
-0.21%+12.44%+32.68%+144.84% 16.91B
+0.42%-5.52%+0.76%+8.50% 13.05B
-1.35%-1.37%-14.02%-30.89% 13.05B
Average +0.40%+2.07%+45.38%+92.17% 24.39B
Weighted average by Cap. +0.68%+0.77%+75.95%+137.05%

Financials

2026 *2027 *
Net sales 8.95M 923K 810K 754K 692K 1.3M 88.86M 1.32M 3.5M 43.69M 3.46M 3.39M 151M 224M 23.15M 20.33M 18.91M 17.35M 32.6M 2.23B 33.1M 87.71M 1.1B 86.89M 85.02M 3.79B
Net income -163M -16.8M -14.76M -13.72M -12.59M -23.66M -1.62B -24.03M -63.67M -795M -63.07M -61.71M -2.75B -18.59M -1.92M -1.68M -1.57M -1.44M -2.7M -185M -2.74M -7.26M -90.74M -7.19M -7.04M -314M
Net Debt -321M -33.13M -29.09M -27.06M -24.83M -46.65M -3.19B -47.37M -126M -1.57B -124M -122M -5.42B -197M -20.31M -17.84M -16.59M -15.22M -28.6M -1.96B -29.05M -76.97M -962M -76.25M -74.61M -3.32B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
25/07/26 SEK 6.510 -3.56% 24,416
23/07/26 SEK 6.750 +3.85% 18,030
22/07/26 SEK 6.500 +1.25% 13,763
21/07/26 SEK 6.420 +2.07% 7,073
20/07/26 SEK 6.290 +4.83% 12,133
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
6.750SEK
Average target price
16.00SEK
Spread / Average Target
+137.04%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock